ClinicalTrials.gg
CompletedNCT05403866BRIGHTUpdated Dec 26, 2025Results posted

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

A Phase 2 interventional study of LT3001 Drug Product and Placebo in Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Lumosa Therapeutics Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 480 studies in Ischemic Stroke with a site in United States — 122 open to participants now, 146 under way, 13 of them phase 3. Ischemic Stroke · United States.

Enrollment
160th of 364
89 · median 66
Started
2022
with 35 others
Phase 2
71 of 480
8 open now
Registered
335th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 160th largest by enrollment of the 364 interventional ones that give a count, is one of 36 that started in 2022, is one of 71 in phase 2, and was the 335th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

122 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)

Read the detailed description

This is a multicenter, double-blind, randomized, and placebo-controlled prospective Phase II clinical study, designed to evaluate LT3001 drug product versus placebo in subjects with AIS. The study is planned to take place in multiple countries. Subjects who participate in this trial should be treated with standard of care of AIS therapies when appropriate.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged 18 to 90 years.
  2. Subject has an NIHSS of 6 to 25.
  3. Subject is able to receive the first IP within 24 hours after stroke symptoms onset.

Neuroimaging Inclusion Criteria:

  1. Subject is able to undergo a contrast brain perfusion with either MRI or computed tomography (CT).
  2. Subject has Target Mismatch Profile on MRI (perfusion is included) or CTP: ischemic core volume ≤70 mL, mismatch ratio ≥1.2 and mismatch volume ≥5 mL.

Exclusion criteria

Exclusion Criteria:

  1. Subject has been treated or intent to treat with endovascular thrombectomy and/or intravenous thrombolytic during the current AIS.
  2. Subject has a pre-stroke disability (mRS ≥2).
  3. Subject has large ischemic core volume >70 mL or ASPECTS ≤5.
  4. Subject has symptoms of suspected subarachnoid hemorrhage.
  5. Subject has imaging evidence of acute intracranial hemorrhage, intracranial tumor, arteriovenous malformations, other central nervous system lesions that could increase the risk of bleeding, or aneurysm requiring treatment.
  6. Subject has significant mass effect with midline shift.
  7. Subject has pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations.
  8. Subject has current uncontrolled hypertension despite treatment.
  9. Subject has >1.7 or abnormal aPTT or count \<100,000/mm\^3.
  10. Subject has received conventional heparin or new oral anticoagulants within 48 hours before the first IP administration.
  11. Subject has blood glucose concentration \<50 mg/dL or >400 mg/dL.
  12. Subject has moderate or severe hepatic, renal, and/or active infectious disease.
  13. Subject is lactating, pregnant, or planning to become pregnant during the study.
  14. Subject has had history of sICH, prior AIS, myocardial infarction, or serious head trauma within 90 days before Screening.
  15. Subject has had any major surgery within 90 days before Screening.
  16. Subject has had a bleeding event within 21 days before Screening.
  17. Subject has puncture of noncompressible vessels within 7 days before Screening.
  18. Subject has participated in another study and received IP within 30 days before Screening or 5 half-lives (whichever is longer).
  19. In the opinion of the Investigator, the subject is not appropriate for the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    LT3001 Drug Product

    Administered by intravenous infusion

    Drug: LT3001 Drug Product

  • Placebo comparator
    Placebo

    Administered by intravenous infusion

    Drug: Placebo

Interventions

  • Administered by intravenous infusion

  • DrugPlacebo

    Administered by intravenous infusion

06

What researchers measure

Primary outcomes

  1. The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration.

    There were no subjects in either treatment group who met the predefined criteria for the primary safety endpoint: the proportion of subjects with TEAEs judged to be probably or definitely related to the IP within 90 days after the first IP administration.

    Time frame: within 90 days after the first IP administration

07

Results

Posted Dec 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneLT3001 Drug ProductPlacebo
Started4345
Completed3742
Not completed63

Outcome measures

PrimaryThe Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration.

There were no subjects in either treatment group who met the predefined criteria for the primary safety endpoint: the proportion of subjects with TEAEs judged to be probably or definitely related to the IP within 90 days after the first IP administration.

Time frame:
within 90 days after the first IP administration
Reported as:
Count of participants · Participants
The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration.
ParticipantsLT3001 Drug ProductPlacebo
The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration.00

Adverse events

Collected over From the time the subject received the first IP until the last follow-up visit, approximately 92 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LT3001 Drug Product4/43 (9.3%)12/43 (27.9%)37/43 (86%)
Placebo1/44 (2.3%)5/44 (11.4%)33/44 (75%)
Most frequent serious events
Most frequent serious events
EventLT3001 Drug ProductPlacebo
Stroke, Brain oedema, Encephalopathy, Neurological decompensationNervous system disorders6/434/44
Colitis ischaemic, Inguinal herniaGastrointestinal disorders2/430/44
Pneumonia, Pneumonia aspirationInfections and infestations2/430/44
Fall, Traumatic subarachnoid haemorrhageInjury, poisoning and procedural complications2/430/44
Leukopenia, NeutropeniaBlood and lymphatic system disorders1/430/44
Cardio-respiratory arrestCardiac disorders0/431/44
Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/431/44
Most frequent other events
Showing 10 of 15
Most frequent other events
EventLT3001 Drug ProductPlacebo
UTI, Pneumonia, Pneumonia aspiration, COVID-19, ConjunctivitisInfections and infestations18/4311/44
Constipation, DiarrhoeaGastrointestinal disorders17/4317/44
Hyperlipidaemia, HypokalaemiaMetabolism and nutrition disorders16/4312/44
Headache, Stroke, Brain oedemaNervous system disorders13/439/44
InsomniaPsychiatric disorders9/4310/44
Arthralgia, Muscle spasmsMusculoskeletal and connective tissue disorders9/437/44
CoughRespiratory, thoracic and mediastinal disorders9/437/44
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders7/433/44
PyrexiaGeneral disorders6/434/44
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications6/433/44

Baseline characteristics

ITT

Age, Categorical
Age, Categorical(Participants)LT3001 Drug ProductPlaceboTotal
<=18 years000
Between 18 and 65 years191938
>=65 years242650
Age, Continuous
Age, Continuous(years)LT3001 Drug ProductPlaceboTotal
Mean67.3 ± 12.2865.7 ± 11.3866.5 ± 11.79
Sex: Female, Male
Sex: Female, Male(Participants)LT3001 Drug ProductPlaceboTotal
Female141327
Male293261
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LT3001 Drug ProductPlaceboTotal
American Indian or Alaska Native000
Asian222042
Native Hawaiian or Other Pacific Islander000
Black or African American303
White182341
More than one race000
Unknown or Not Reported022
Weight
Weight(Kg)LT3001 Drug ProductPlaceboTotal
Mean74.75 ± 16.72374.28 ± 17.82774.51 ± 17.198
08

Study locations

1 site
  • Chattanooga Center for Neurologic Research
    Chattanooga, Tennessee 37403, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in May 2025, 33 months.

Results were first posted in Dec 2025, 7 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 33 months is above that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Jun 3, 2022
StartActual
Aug 17, 2022
Primary completionActual
May 23, 2025
CompletionActual
May 23, 2025
Results first posted
Dec 26, 2025
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05403866
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Aug 17, 2022
Primary completion
May 23, 2025
Completion
May 23, 2025
Results posted
Dec 26, 2025
Last update
Dec 26, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LT3001

Start the discussion